The combination of the eight genes (NFE2L2, CSMD1, CREBBP, KALRN, PRUNE2, NRXN1, AKAP9, FREM2) with more pronounced prognostic predictivity in a unique panel allowed the opportunity to define a mutational score and to evaluate its prognostic impact on the whole population of ESCC patients showing that patients with one mutation in one of these eight genes have an intermediate prognosis, while those with two or more mutations have a lower survival compared to those with no mutations in these eight genes [32]. The gene discussed is NFE2L2; the disease is esophageal squamous cell carcinoma.